Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing <scp>NLRP</scp>3 inflammasome activation in <scp>APP</scp>/<scp>PS</scp>1 transgenic mice

Abstract

Taken together, our findings suggest that DHM prevents progression of AD-like pathology through inhibition of NLRP3 inflammasome-based microglia-mediated neuroinflammation and may be a promising therapeutic drug for treating AD.